@article{c9195cbd866744bcbd980080963967b6,
title = "Executive summary: International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases",
abstract = "A Panel of International Experts was convened by the Infectious Diseases Society of America (IDSA) in collaboration with the European Society for Microbiology and Infectious Diseases (ESCMID) to update the 1999 Uncomplicated Urinary Tract Infection Guidelines by the IDSA. Co-sponsoring organizations include the American Congress of Obstetricians and Gynecologists, American Urological Association, Association of Medical Microbiology and Infectious Diseases-Canada, and the Society for Academic Emergency Medicine. The focus of this work is treatment of women with acute uncomplicated cystitis and pyelonephritis, diagnoses limited in these guidelines to premenopausal, non-pregnant women with no known urological abnormalities or co-morbidities. The issues of in vitro resistance prevalence and the ecological adverse effects of antimicrobial therapy (collateral damage) were considered as important factors in making optimal treatment choices and thus are reflected in the rankings of recommendations.",
author = "Kalpana Gupta and Hooton, {Thomas M.} and Naber, {Kurt G.} and Bj{\"o}rn Wullt and Richard Colgan and Miller, {Loren G.} and Moran, {Gregory J.} and Nicolle, {Lindsay E.} and Raul Raz and Schaeffer, {Anthony J.} and Soper, {David E.}",
note = "Funding Information: Potential conflicts of interest. K.G. (Chair) has served as a consultant to Pfizer and Pinnacle Pharmaceutical.A.J.S. has served as a consultant to Novabay Pharmaceuticals, Pfizer, Propagate Pharmaceuticals, Hagen/Sinclair Research Recruiting, Swiss Precision Diagnostics Development Company, and FlashPointMedica; has received honoraria from BMJ Group (British Medical Journal) and Advanstar Communications; received a royalty payment from UpToDate; and received remuneration from the American Urological Association. G.J.M. has served as a consultant to Cerexa, Cubist, Eisai, Forest, Merck, Ortho-McNeil, Pfizer, and Schering-Plough and has received honoraria from Cubist and Merck. K.G.N. has received remuneration as consultant or speaker from Bionorica, Daiichi Sankyo, Janssen Cilag, Johnson & Johnson, OM Pharma, Pierre Fabre, Sanofi Aventis, and Zambon and has received research grants from MerLion Pharmaceuticals, Rosen Pharma, and OM Pharma.L.E.N. has served as a consultant to Pfizer, Leo pharmaceuticals, Cerexa, and Johnson & Johnson and served on the advisory board for Leo Pharmaceuticals and Cerexa.L.G.M. has served as a consultant to Forest and Theravance Laboratories and received research grants from Cubist and Pfizer Pharmaceuticals. T.M.H. has served as a consultant to Pfizer, Alita Pharmaceuticals, and Pinnacle Pharmaceuticals All other authors: no conflicts.",
year = "2011",
month = mar,
day = "1",
doi = "10.1093/cid/cir102",
language = "English (US)",
volume = "52",
pages = "561--564",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",
}